Staidson Beijing BioPharmaceuticals Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 272.632 million compared to CNY 165.982 million a year ago. Operating loss was CNY 59.660 million compared to CNY 58.287 million a year ago. Net loss was CNY 59.811 million compared to CNY 74.978 million a year ago. Basic loss per share from continuing operations was CNY 0.13 compared to CNY 0.16 a year ago.